vs

Side-by-side financial comparison of CRISPR Therapeutics AG (CRSP) and LandBridge Co LLC (LB). Click either name above to swap in a different company.

LandBridge Co LLC is the larger business by last-quarter revenue ($51.0M vs $35.7M, roughly 1.4× CRISPR Therapeutics AG). LandBridge Co LLC runs the higher net margin — 35.0% vs -104.5%, a 139.6% gap on every dollar of revenue. On growth, LandBridge Co LLC posted the faster year-over-year revenue change (16.0% vs -82.3%). LandBridge Co LLC produced more free cash flow last quarter ($40.9M vs $-50.3M).

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...

CRSP vs LB — Head-to-Head

Bigger by revenue
LB
LB
1.4× larger
LB
$51.0M
$35.7M
CRSP
Growing faster (revenue YoY)
LB
LB
+98.3% gap
LB
16.0%
-82.3%
CRSP
Higher net margin
LB
LB
139.6% more per $
LB
35.0%
-104.5%
CRSP
More free cash flow
LB
LB
$91.2M more FCF
LB
$40.9M
$-50.3M
CRSP

Income Statement — Q4 FY2024 vs Q1 FY2026

Metric
CRSP
CRSP
LB
LB
Revenue
$35.7M
$51.0M
Net Profit
$-37.3M
$17.9M
Gross Margin
Operating Margin
-181.0%
57.2%
Net Margin
-104.5%
35.0%
Revenue YoY
-82.3%
16.0%
Net Profit YoY
-141.8%
15.6%
EPS (diluted)
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRSP
CRSP
LB
LB
Q1 26
$51.0M
Q4 25
$56.8M
Q3 25
$50.8M
Q2 25
$47.5M
Q1 25
$44.0M
Q4 24
$35.7M
$36.5M
Q3 24
$28.5M
Q2 24
$26.0M
Net Profit
CRSP
CRSP
LB
LB
Q1 26
$17.9M
Q4 25
$8.1M
Q3 25
$8.1M
Q2 25
$7.5M
Q1 25
$6.5M
Q4 24
$-37.3M
$49.3M
Q3 24
$2.7M
Q2 24
$-57.7M
Operating Margin
CRSP
CRSP
LB
LB
Q1 26
57.2%
Q4 25
60.0%
Q3 25
60.8%
Q2 25
60.0%
Q1 25
57.0%
Q4 24
-181.0%
49.4%
Q3 24
11.2%
Q2 24
-197.4%
Net Margin
CRSP
CRSP
LB
LB
Q1 26
35.0%
Q4 25
14.2%
Q3 25
15.9%
Q2 25
15.8%
Q1 25
14.7%
Q4 24
-104.5%
135.2%
Q3 24
9.3%
Q2 24
-222.1%
EPS (diluted)
CRSP
CRSP
LB
LB
Q1 26
Q4 25
$0.24
Q3 25
$0.26
Q2 25
$0.24
Q1 25
$0.20
Q4 24
$-0.41
Q3 24
$-0.04
Q2 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRSP
CRSP
LB
LB
Cash + ST InvestmentsLiquidity on hand
$1.9B
$29.7M
Total DebtLower is stronger
$433.0K
Stockholders' EquityBook value
$1.9B
Total Assets
$2.2B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRSP
CRSP
LB
LB
Q1 26
$29.7M
Q4 25
$30.7M
Q3 25
$28.3M
Q2 25
$20.3M
Q1 25
$14.9M
Q4 24
$1.9B
$37.0M
Q3 24
$14.4M
Q2 24
$24.6M
Total Debt
CRSP
CRSP
LB
LB
Q1 26
$433.0K
Q4 25
$570.7M
Q3 25
$366.1M
Q2 25
$370.9M
Q1 25
$375.5M
Q4 24
$385.5M
Q3 24
$242.4M
Q2 24
$360.8M
Stockholders' Equity
CRSP
CRSP
LB
LB
Q1 26
Q4 25
$340.3M
Q3 25
$272.0M
Q2 25
$266.4M
Q1 25
$217.0M
Q4 24
$1.9B
$211.8M
Q3 24
$97.2M
Q2 24
$296.4M
Total Assets
CRSP
CRSP
LB
LB
Q1 26
$1.4B
Q4 25
$1.4B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.0B
Q4 24
$2.2B
$1.0B
Q3 24
$689.9M
Q2 24
$710.5M
Debt / Equity
CRSP
CRSP
LB
LB
Q1 26
Q4 25
1.68×
Q3 25
1.35×
Q2 25
1.39×
Q1 25
1.73×
Q4 24
1.82×
Q3 24
2.49×
Q2 24
1.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRSP
CRSP
LB
LB
Operating Cash FlowLast quarter
$-50.0M
$41.1M
Free Cash FlowOCF − Capex
$-50.3M
$40.9M
FCF MarginFCF / Revenue
-140.9%
80.3%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
2.30×
TTM Free Cash FlowTrailing 4 quarters
$-325.9M
$232.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRSP
CRSP
LB
LB
Q1 26
$41.1M
Q4 25
$126.3M
Q3 25
$34.9M
Q2 25
$37.3M
Q1 25
$15.9M
Q4 24
$-50.0M
$67.6M
Q3 24
$7.5M
Q2 24
$16.0M
Free Cash Flow
CRSP
CRSP
LB
LB
Q1 26
$40.9M
Q4 25
$122.0M
Q3 25
$33.7M
Q2 25
$36.1M
Q1 25
$15.8M
Q4 24
$-50.3M
$66.7M
Q3 24
$7.1M
Q2 24
$15.7M
FCF Margin
CRSP
CRSP
LB
LB
Q1 26
80.3%
Q4 25
214.9%
Q3 25
66.3%
Q2 25
75.9%
Q1 25
36.0%
Q4 24
-140.9%
182.6%
Q3 24
25.1%
Q2 24
60.4%
Capex Intensity
CRSP
CRSP
LB
LB
Q1 26
Q4 25
7.5%
Q3 25
2.3%
Q2 25
2.6%
Q1 25
0.2%
Q4 24
0.7%
2.7%
Q3 24
1.1%
Q2 24
1.4%
Cash Conversion
CRSP
CRSP
LB
LB
Q1 26
2.30×
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
Q1 25
2.46×
Q4 24
1.37×
Q3 24
2.80×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRSP
CRSP

Collaboration Revenue$35.0M98%
Grant$2.3M6%

LB
LB

Other$14.2M28%
Easements and other surface-related revenues$11.6M23%
Surface use royalties - related party$11.0M22%
Resource sales$5.2M10%
Resource royalties$4.3M8%
Easements and other surface-related revenues - related party$3.2M6%
Resource royalties - related party$1.3M2%
Resource sales - related party$205.0K0%

Related Comparisons